Advisory Services Network’s BioXcel Therapeutics BTAI Stock Holding History

Advisory Services Network’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24	Closed	-$7.13K	–	1744
2023 Q1	$7.13K	Hold	24	–	–	﹤0.01%	3008
2022 Q4	$8.21K	Buy	+24	New	+$5.8K	﹤0.01%	2934
2021 Q3	–	Sell	-20	Closed	-$9K	–	1645
2021 Q2	$9K	Buy	+20	New	+$10.9K	﹤0.01%	2827
2021 Q1	–	Sell	-20	Closed	-$15K	–	1500
2020 Q4	$15K	Hold	20	–	–	﹤0.01%	2241
2020 Q3	$14K	Buy	+20	New	+$15K	﹤0.01%	2230
2020 Q2	–	Sell	-19	Closed	-$7K	–	1257
2020 Q1	$7K	Buy	+19	New	+$6.83K	﹤0.01%	2323

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Advisory Services Network's BTAI Position: Q2 2023 in Review

Advisory Services Network sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 24 shares — an estimated $7.13K sold.

Advisory Services Network first reported a position in BTAI in Q1 2020 and held it in 6 quarters. The position peaked at $15K in Q4 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

Advisory Services Network reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 24 BioXcel Therapeutics shares in Q2 2023, an estimated $7.13K.
Advisory Services Network first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 6 quarters.
Advisory Services Network's BioXcel Therapeutics position peaked at $15K in Q4 2020.
88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.